[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.] #  @avidresearch avidresearch avidresearch posts on X about $iobt, $ovid, $idya, combo the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours. ### Engagements: XXXXX [#](/creator/twitter::82162291/interactions)  - X Week XXXXXX +145% - X Month XXXXXXX +17% - X Months XXXXXXX -XX% - X Year XXXXXXXXX +160% ### Mentions: XX [#](/creator/twitter::82162291/posts_active)  - X Week XX +7.70% - X Month XX +38% - X Months XXX -XX% - X Year XXX +136% ### Followers: XXXXXX [#](/creator/twitter::82162291/followers)  - X Week XXXXXX -XXXX% - X Month XXXXXX +2.20% - X Months XXXXXX +8.50% - X Year XXXXXX +14% ### CreatorRank: XXXXXXX [#](/creator/twitter::82162291/influencer_rank)  ### Social Influence [#](/creator/twitter::82162291/influence) --- **Social category influence** [stocks](/list/stocks) XXXX% [finance](/list/finance) XXXX% **Social topic influence** [$iobt](/topic/$iobt) #4, [$ovid](/topic/$ovid) 2.63%, [$idya](/topic/$idya) #13, [combo](/topic/combo) #1592, [$pfe](/topic/$pfe) #256, [$mrna](/topic/$mrna) #37, [$cldx](/topic/$cldx) 0.66%, [$178b](/topic/$178b) 0.66%, [$rapt](/topic/$rapt) 0.66%, [$imcr](/topic/$imcr) XXXX% **Top accounts mentioned or mentioned by** [@jeromeleonard5](/creator/undefined) [@267capital](/creator/undefined) [@epickram](/creator/undefined) [@houndcl](/creator/undefined) [@oncinvestor](/creator/undefined) [@financebully](/creator/undefined) [@jacobplieth](/creator/undefined) [@nociftw](/creator/undefined) [@notgenentech](/creator/undefined) [@plainyogurt21](/creator/undefined) [@banana_oncology](/creator/undefined) [@jfais20](/creator/undefined) [@biohazard3737](/creator/undefined) [@monacobiotech](/creator/undefined) [@aaronrosenblum5](/creator/undefined) [@bluejaunt100](/creator/undefined) [@pickingmyown](/creator/undefined) [@stl_biotech](/creator/undefined) [@stlbiotech](/creator/undefined) [@semodough](/creator/undefined) **Top assets mentioned** [IDEAYA Biosciences, Inc. Common Stock (IDYA)](/topic/$idya) [Pfizer, Inc. (PFE)](/topic/$pfe) [Moderna Inc (MRNA)](/topic/$mrna) [Celldex Therapeutics, Inc (CLDX)](/topic/$cldx) [Novo-Nordisk (NVO)](/topic/$nvo) [Biohaven Pharmaceutical Holding Company Ltd. (BHVN)](/topic/$bhvn) [uniQure N.V. (QURE)](/topic/$qure) [MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX)](/topic/$mltx) [Immunovant, Inc. Common Stock (IMVT)](/topic/$imvt) [Oklo Inc. (OKLO)](/topic/$oklo) ### Top Social Posts [#](/creator/twitter::82162291/posts) --- Top posts by engagements in the last XX hours "Yep. Looks like higher IgE reductions translating to directionally better efficacy. They could easily statistically differentiate vs Omalizumab in a large enough trial. $CLDX mktcap $1.78B except RPT904 also has the huge food allergy potential (go after Oma excluded on label) $RAPT" [X Link](https://x.com/avidresearch/status/1980247346823762055) [@avidresearch](/creator/x/avidresearch) 2025-10-20T12:18Z 11.3K followers, 1367 engagements "For context $IMCR which is only approved in HLA +ve MUM (30-40%) and has a shorter PFS (3.3 months vs 7.x for Daro) has EV of $1B $IDYA" [X Link](https://x.com/avidresearch/status/1961457803291193406) [@avidresearch](/creator/x/avidresearch) 2025-08-29T15:55Z 11.3K followers, 3150 engagements "$PFE Mktcap is $140B. They will invest $70B in manufacturing in US" [X Link](https://x.com/avidresearch/status/1973050548052967688) [@avidresearch](/creator/x/avidresearch) 2025-09-30T15:41Z 11.3K followers, 11.7K engagements "Dont understand $PFE price action. How does the deal reached yesterday have any impact on the pipeline (true valuation)" [X Link](https://x.com/avidresearch/status/1973378615975854357) [@avidresearch](/creator/x/avidresearch) 2025-10-01T13:25Z 11.3K followers, 5954 engagements "$mrna copying $IOBT MOA. Good data" [X Link](https://x.com/avidresearch/status/1977497063064805463) [@avidresearch](/creator/x/avidresearch) 2025-10-12T22:10Z 11.3K followers, 7722 engagements "Acting like a buyout candidate" [X Link](https://x.com/avidresearch/status/1978194638096711766) [@avidresearch](/creator/x/avidresearch) 2025-10-14T20:22Z 11.3K followers, 3742 engagements "@semodough Think $NVO is FINALLY diversifying out of obesity" [X Link](https://x.com/avidresearch/status/1978445402387906881) [@avidresearch](/creator/x/avidresearch) 2025-10-15T12:58Z 11.3K followers, 1061 engagements "$IDYA its easy to get lost in the flurry of data updates but this combo with Trodelvy in urothelial cancer is actually quite good" [X Link](https://x.com/avidresearch/status/1965040803795120554) [@avidresearch](/creator/x/avidresearch) 2025-09-08T13:13Z 11.3K followers, 5897 engagements "$BHVN might pull a $QURE if it gets troriluzole gets approved. 3-yr data vs external controls" [X Link](https://x.com/avidresearch/status/1970899909453709331) [@avidresearch](/creator/x/avidresearch) 2025-09-24T17:15Z 11.3K followers, 38.9K engagements "$IOBT if only they waited for few more events. What a tragic outcome for these guys" [X Link](https://x.com/avidresearch/status/1972629779074756892) [@avidresearch](/creator/x/avidresearch) 2025-09-29T11:49Z 11.3K followers, 2733 engagements "If you dodged $MLTX $KALA $IOBT $LRMR $APLT Congrats" [X Link](https://x.com/avidresearch/status/1972634581435039824) [@avidresearch](/creator/x/avidresearch) 2025-09-29T12:08Z 11.3K followers, 26.1K engagements "Fair to say $MRNA inferior to $IOBT (based on pd1 -ve data)" [X Link](https://x.com/avidresearch/status/1977708909511991415) [@avidresearch](/creator/x/avidresearch) 2025-10-13T12:12Z 11.3K followers, 7339 engagements "@AaronRosenblum5 @KingachillesE @monaco_biotech Combo tolerability is key since that is the only way forward. Mono data looks great though" [X Link](https://x.com/avidresearch/status/1979557814399087033) [@avidresearch](/creator/x/avidresearch) 2025-10-18T14:38Z 11.3K followers, XXX engagements "ESMO data deluge reminds me why @Sports_bios said oncology is so challenging to evaluate. Too many datasets to compare" [X Link](https://x.com/avidresearch/status/1979884792532586827) [@avidresearch](/creator/x/avidresearch) 2025-10-19T12:18Z 11.3K followers, 3842 engagements "@BiotechSho99376 A single XXX mg dose of RPT904 showed numerically superior efficacy to four XXX mg doses of omalizumab at week 16* *Study is not a formal non-inferiority study; no statistical hypothesis is being tested" [X Link](https://x.com/avidresearch/status/1980251146045264139) [@avidresearch](/creator/x/avidresearch) 2025-10-20T12:33Z 11.3K followers, XXX engagements "$IMVT down on no news" [X Link](https://x.com/avidresearch/status/1948731909057785921) [@avidresearch](/creator/x/avidresearch) 2025-07-25T13:07Z 11.3K followers, 2440 engagements "$OVID X potentially good drugs" [X Link](https://x.com/avidresearch/status/1974139678250184863) [@avidresearch](/creator/x/avidresearch) 2025-10-03T15:49Z 11.3K followers, 4844 engagements "@bluejaunt100 Think they characterized the vision risk from 1st gen drug well (ocular accumulation) and while early XXX was rationally designed to avoid that tox. $OVID Cc @houndcl" [X Link](https://x.com/avidresearch/status/1974141401576452488) [@avidresearch](/creator/x/avidresearch) 2025-10-03T15:56Z 11.3K followers, XXX engagements "@JoseRestonVA @HeikwanTrades $OVID data release was a lot better than many realized. Biomarker data confirms there is high probability of efficacy translating (exceeding 1st gen drug) plus safety which was incredibly benign" [X Link](https://x.com/avidresearch/status/1974801347477442672) [@avidresearch](/creator/x/avidresearch) 2025-10-05T11:38Z 11.3K followers, XXX engagements "@jfais20 Interesting alternative take. At end of the day Vigabatrin is very effective for patients with refractory seizures who haven't responded to other treatments. $OVID Management thesis that OV329 could be a more efficacious and safer alternative is very much intact" [X Link](https://x.com/avidresearch/status/1974953835375591649) [@avidresearch](/creator/x/avidresearch) 2025-10-05T21:44Z 11.3K followers, 1515 engagements "$OKLO barely any revenues. If we use biotech valuation methods this would trade at $1" [X Link](https://x.com/avidresearch/status/1978454293054148910) [@avidresearch](/creator/x/avidresearch) 2025-10-15T13:33Z 11.3K followers, 2134 engagements
[GUEST ACCESS MODE: Data is scrambled or limited to provide examples. Make requests using your API key to unlock full data. Check https://lunarcrush.ai/auth for authentication information.]
@avidresearch avidresearch
avidresearch posts on X about $iobt, $ovid, $idya, combo the most. They currently have XXXXXX followers and XXX posts still getting attention that total XXXXX engagements in the last XX hours.
Engagements: XXXXX #
- X Week XXXXXX +145%
- X Month XXXXXXX +17%
- X Months XXXXXXX -XX%
- X Year XXXXXXXXX +160%
Mentions: XX #
- X Week XX +7.70%
- X Month XX +38%
- X Months XXX -XX%
- X Year XXX +136%
Followers: XXXXXX #
- X Week XXXXXX -XXXX%
- X Month XXXXXX +2.20%
- X Months XXXXXX +8.50%
- X Year XXXXXX +14%
CreatorRank: XXXXXXX #
Social Influence #
Social category influence stocks XXXX% finance XXXX%
Social topic influence $iobt #4, $ovid 2.63%, $idya #13, combo #1592, $pfe #256, $mrna #37, $cldx 0.66%, $178b 0.66%, $rapt 0.66%, $imcr XXXX%
Top accounts mentioned or mentioned by @jeromeleonard5 @267capital @epickram @houndcl @oncinvestor @financebully @jacobplieth @nociftw @notgenentech @plainyogurt21 @banana_oncology @jfais20 @biohazard3737 @monacobiotech @aaronrosenblum5 @bluejaunt100 @pickingmyown @stl_biotech @stlbiotech @semodough
Top assets mentioned IDEAYA Biosciences, Inc. Common Stock (IDYA) Pfizer, Inc. (PFE) Moderna Inc (MRNA) Celldex Therapeutics, Inc (CLDX) Novo-Nordisk (NVO) Biohaven Pharmaceutical Holding Company Ltd. (BHVN) uniQure N.V. (QURE) MoonLake Immunotherapeutics Class A Ordinary Shares (MLTX) Immunovant, Inc. Common Stock (IMVT) Oklo Inc. (OKLO)
Top Social Posts #
Top posts by engagements in the last XX hours
"Yep. Looks like higher IgE reductions translating to directionally better efficacy. They could easily statistically differentiate vs Omalizumab in a large enough trial. $CLDX mktcap $1.78B except RPT904 also has the huge food allergy potential (go after Oma excluded on label) $RAPT"
X Link @avidresearch 2025-10-20T12:18Z 11.3K followers, 1367 engagements
"For context $IMCR which is only approved in HLA +ve MUM (30-40%) and has a shorter PFS (3.3 months vs 7.x for Daro) has EV of $1B $IDYA"
X Link @avidresearch 2025-08-29T15:55Z 11.3K followers, 3150 engagements
"$PFE Mktcap is $140B. They will invest $70B in manufacturing in US"
X Link @avidresearch 2025-09-30T15:41Z 11.3K followers, 11.7K engagements
"Dont understand $PFE price action. How does the deal reached yesterday have any impact on the pipeline (true valuation)"
X Link @avidresearch 2025-10-01T13:25Z 11.3K followers, 5954 engagements
"$mrna copying $IOBT MOA. Good data"
X Link @avidresearch 2025-10-12T22:10Z 11.3K followers, 7722 engagements
"Acting like a buyout candidate"
X Link @avidresearch 2025-10-14T20:22Z 11.3K followers, 3742 engagements
"@semodough Think $NVO is FINALLY diversifying out of obesity"
X Link @avidresearch 2025-10-15T12:58Z 11.3K followers, 1061 engagements
"$IDYA its easy to get lost in the flurry of data updates but this combo with Trodelvy in urothelial cancer is actually quite good"
X Link @avidresearch 2025-09-08T13:13Z 11.3K followers, 5897 engagements
"$BHVN might pull a $QURE if it gets troriluzole gets approved. 3-yr data vs external controls"
X Link @avidresearch 2025-09-24T17:15Z 11.3K followers, 38.9K engagements
"$IOBT if only they waited for few more events. What a tragic outcome for these guys"
X Link @avidresearch 2025-09-29T11:49Z 11.3K followers, 2733 engagements
"If you dodged $MLTX $KALA $IOBT $LRMR $APLT Congrats"
X Link @avidresearch 2025-09-29T12:08Z 11.3K followers, 26.1K engagements
"Fair to say $MRNA inferior to $IOBT (based on pd1 -ve data)"
X Link @avidresearch 2025-10-13T12:12Z 11.3K followers, 7339 engagements
"@AaronRosenblum5 @KingachillesE @monaco_biotech Combo tolerability is key since that is the only way forward. Mono data looks great though"
X Link @avidresearch 2025-10-18T14:38Z 11.3K followers, XXX engagements
"ESMO data deluge reminds me why @Sports_bios said oncology is so challenging to evaluate. Too many datasets to compare"
X Link @avidresearch 2025-10-19T12:18Z 11.3K followers, 3842 engagements
"@BiotechSho99376 A single XXX mg dose of RPT904 showed numerically superior efficacy to four XXX mg doses of omalizumab at week 16* *Study is not a formal non-inferiority study; no statistical hypothesis is being tested"
X Link @avidresearch 2025-10-20T12:33Z 11.3K followers, XXX engagements
"$IMVT down on no news"
X Link @avidresearch 2025-07-25T13:07Z 11.3K followers, 2440 engagements
"$OVID X potentially good drugs"
X Link @avidresearch 2025-10-03T15:49Z 11.3K followers, 4844 engagements
"@bluejaunt100 Think they characterized the vision risk from 1st gen drug well (ocular accumulation) and while early XXX was rationally designed to avoid that tox. $OVID Cc @houndcl"
X Link @avidresearch 2025-10-03T15:56Z 11.3K followers, XXX engagements
"@JoseRestonVA @HeikwanTrades $OVID data release was a lot better than many realized. Biomarker data confirms there is high probability of efficacy translating (exceeding 1st gen drug) plus safety which was incredibly benign"
X Link @avidresearch 2025-10-05T11:38Z 11.3K followers, XXX engagements
"@jfais20 Interesting alternative take. At end of the day Vigabatrin is very effective for patients with refractory seizures who haven't responded to other treatments. $OVID Management thesis that OV329 could be a more efficacious and safer alternative is very much intact"
X Link @avidresearch 2025-10-05T21:44Z 11.3K followers, 1515 engagements
"$OKLO barely any revenues. If we use biotech valuation methods this would trade at $1"
X Link @avidresearch 2025-10-15T13:33Z 11.3K followers, 2134 engagements